Positions in Galectin Therapeutics Inc. (NASDAQ: GALT)
In the second quarter of 2018, Galectin Therapeutics Inc. (NASDAQ: GALT) dropped to 1.5 after SEC filing. It is less than -0.36, from 2018Q1 it is 1.86. 27 investment managers began new and increased equity positions, while 18 reduced and sold shares in Galectin Therapeutics Inc, which resulted in a worsening mood. The Fund owns 4.60 million shares, which is 4.02 million shares in 2018.Q1. A year The Galactic Therapy Engineering located in the 10 most popular locations was similar to a number from 0 to 0. In total, 7 funds closed positions, 11 decreased and 14 increased. Also, 13 funds bought new rates for Galectin Therapeutics Inc.
Largest Galectin Therapy Inc. Investors
In the 2nd quarter of 2007, Benchmark Capital Advisors owns 221,700 shares of Galectin Therapeutics Inc. 2018 In the 2nd quarter of the year, 218,429 shares of Galectin Therapeutics Inc. are owned by Eam Investors Llc. Cutter & Co Brokerage Inc. reported 54,000 shares. Tennessee-based Courage Capital Management Llc has invested around 0.11% of Galactin Therapeutics Inc.'s active portfolio of asset managers. Montana Foundation D.A. Davidson & Co owns 656,527 shares or 0.08% of their US long-term venture risk.
Galectin Therapeutics, Inc., a clinical clinical biopharmaceutical company, deals with the research and development of fibrotic diseases and cancer therapies. The company has a $ 197.61 million biggest market constraint. The company's main product candidate includes a galectin-3 inhibitor, galactoabine-rhamnogalakturonan polysaccharide polymer for hepatic fibrosis and cirrhosis of the liver in non-alcoholic steatohepatitis patients, and cancer treatment. It currently has a negative income. It also deals with the development of GM-CT-01, a pre-clinical development for the treatment of cardiovascular fibrosis, and focuses on the development of GR-MD-02 for the treatment of psoriasis.
In the last trading session, shares rose by 1.05% or $ 0.05, touching $ 4.83. Galecticon Therapeutics, Inc. is 151 080 shares. Since November 12, 2017, GALT has grown by 208% and is growing. Stocks surpassed S & P500 by 192.38%.
Geode Capital Limited Com owns 202,563 shs or 0% of its equity. New York Millennium Mngmt Ltd Responsibility Corporation has invested 0% in Galectin Therapeutics, Inc. (NASDAQ: GALT). The Canadian Bank Royal Bank of Canada, Ontario – Canada Fund, reported 1600 shs. Buckingham Asset Mgmt Ltd Llc invested 0.01% or 10,000 shs. 47,550 is owned by the State Street. Art Advsr Limited holds 0.01% of Galectin Therapeutics, Inc. (NASDAQ: GALT) or 31.882 shs. Illinois-based Group One Trading Ltd Partnership has invested 0.01% in Galectin Therapeutics, Inc. (NASDAQ: GALT). Cutter & Brokerage Inc. owns 54,000 shs. Tower Rech Capital Ltd Responsibility Corp (Trc) Owned by 0% Galectin Therapeutics, Inc. (NASDAQ: GALT) or 1094 shs. Sei Invests Com accrued 0% or 3800 shs. Dynamic Advisor for solutions in your capital is 0.01% or 10,000 sh. Deutsche Bancorporation Ag owns 0% of Galectin Therapeutics, Inc. capital (NASDAQ: GALT) for 1,302 shs. 218,429 earned by Eam Invests Lc. Jane Street Gp Lc owns 1,4369 shs for 0% of its capital. Pnc Fincl Serv Group accumulates 52,164 shs or 0% of shares.
Since May 31, 2018, Galectin Therapeutics, Inc. There were 23 acquisitions of internal sales and 1 inside information. This net activity is $ 14.94 million. Thursday, June 14, CZIRR JAMES C. CZIRR JAMES On Monday, June 4th, Shlevin Harold H. sold to Galectin Therapeutics, Inc. (NASDAQ: GALT) worth $ 107,356 worth of trading for $ 151,860 worth $ 1.31 million. On Wednesday, June 13, CALLICUTT JACK W. TRABER PETER G sold 65,167 shares worth of shares. On Wednesday, June 13th, on Wednesday, June 13, Galectin Therapeutics, Inc. was sold. (NASDAQ: GALT) worth $ 751,000. Rubin Marc sells a value of $ 353,312 worth of shares. LEWIS JOEL bought $ 7,058 for Galectin Therapeutics, Inc. Securities (NASDAQ: GALT) or 1000 cells on Monday, June 25th.
For more information on Galectin Therapeutics, Inc. (NASDAQ: GALT) news release at a glance: Nasdaq.com, Globenewswire.com, Benzinga.com, Benzinga.com or Seekingalpha.com. The titles are as follows: "Exalenz Bioscience aggregated data in Galectin Therapy", Phase 2 of the NASH-CX Study GR-MD-02 to be presented … "released on November 5, 2018," Galectin Therapeutics to participate in the ROTH Capital Battle of NASH Thrones Investment Conference "On October 14, 2018," The 75 Most Remittances From Yesterday ", with the publication date: on November 7, 2018, the" 52 major shifters from yesterday "and the latest" Key Events of the Next Week – Healthcare "with publication Date: November 2, 2018.
Receive news and ratings by email – Enter your email address below to receive a concise summary daily newsletter and analytics ratings with our FREE daily email newsletter.